JP2019530431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530431A5 JP2019530431A5 JP2019504106A JP2019504106A JP2019530431A5 JP 2019530431 A5 JP2019530431 A5 JP 2019530431A5 JP 2019504106 A JP2019504106 A JP 2019504106A JP 2019504106 A JP2019504106 A JP 2019504106A JP 2019530431 A5 JP2019530431 A5 JP 2019530431A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- sequence
- car
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 66
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 51
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 102100032530 Glypican-3 Human genes 0.000 claims description 2
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366729P | 2016-07-26 | 2016-07-26 | |
| US201662366731P | 2016-07-26 | 2016-07-26 | |
| US62/366,729 | 2016-07-26 | ||
| US62/366,731 | 2016-07-26 | ||
| PCT/EP2017/068654 WO2018019772A1 (en) | 2016-07-26 | 2017-07-24 | Chimeric antigen receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019530431A JP2019530431A (ja) | 2019-10-24 |
| JP2019530431A5 true JP2019530431A5 (enExample) | 2020-09-03 |
Family
ID=59569287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504106A Withdrawn JP2019530431A (ja) | 2016-07-26 | 2017-07-24 | キメラ抗原受容体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190262397A1 (enExample) |
| EP (1) | EP3490589A1 (enExample) |
| JP (1) | JP2019530431A (enExample) |
| KR (1) | KR20190038567A (enExample) |
| CN (1) | CN110035768A (enExample) |
| AU (1) | AU2017301826A1 (enExample) |
| CA (1) | CA3031846A1 (enExample) |
| SG (1) | SG11201900634VA (enExample) |
| TW (1) | TW201806969A (enExample) |
| WO (1) | WO2018019772A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102529012B1 (ko) * | 2016-04-22 | 2023-05-09 | 크라제 메디컬 씨오 리미티드 | 세포성 면역요법을 위한 조성물 및 방법 |
| CN110573528B (zh) * | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 针对共刺激性tnf受体的双特异性抗原结合分子 |
| CN108913709A (zh) * | 2018-06-26 | 2018-11-30 | 山东兴瑞生物科技有限公司 | 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法 |
| WO2020017479A1 (ja) * | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | 抗ｇｐｃ３一本鎖抗体を含むｃａｒ |
| US11691976B2 (en) * | 2018-08-23 | 2023-07-04 | Promega Corporation | Coelenterazine analogues |
| EP3860716A2 (en) * | 2018-10-01 | 2021-08-11 | Adicet Bio Inc. | Compositions and methods regarding engineered and non-engineered gamma-delta -t cells for treatment of solid tumors |
| CN112300288B (zh) * | 2019-07-29 | 2022-08-02 | 济南赛尔生物科技股份有限公司 | 一种cik细胞的嵌合抗原受体car及其应用 |
| JP2022547220A (ja) * | 2019-09-10 | 2022-11-10 | サイトイミューン セラピューティクス， インコーポレイテッド | 二重特異性抗体ｃａｒ細胞免疫療法 |
| US20240115602A1 (en) * | 2019-10-07 | 2024-04-11 | Fate Therapeutics, Inc. | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
| CN110790842B (zh) * | 2019-11-25 | 2021-03-30 | 贵州康钦承平生物科技有限公司 | 一种FasL-CAR融合蛋白和表达融合蛋白的T细胞及其制备方法和应用 |
| BR112022011957A2 (pt) * | 2019-12-20 | 2022-09-06 | Medimmune Llc | Composições e métodos de tratamento de câncer com receptores de antígenos quiméricos visando glipicana 3 |
| CN113087806B (zh) * | 2019-12-31 | 2022-09-06 | 华东师范大学 | 靶向多种肿瘤的新型car-t细胞及其制备和方法 |
| KR20220155588A (ko) * | 2020-03-18 | 2022-11-23 | 주식회사 유틸렉스 | Gpc3 car-t 세포 조성물 및 이의 제조 및 사용 방법 |
| CA3176125A1 (en) * | 2020-03-18 | 2021-09-23 | Eutilex Co., Ltd. | Gpc3 car- t cells secreting il-18 and methods of making and using the same |
| CN112225822B (zh) * | 2020-12-14 | 2021-03-23 | 北京基因启明生物科技有限公司 | 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用 |
| CA3229688A1 (en) * | 2021-08-27 | 2023-03-02 | Hao GUO | Chimeric antigen receptor and use thereof |
| WO2025061004A1 (zh) * | 2023-09-19 | 2025-03-27 | 苏州沙砾生物科技有限公司 | 一种融合蛋白及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1629013B1 (en) | 2003-05-31 | 2018-01-24 | Amgen Research (Munich) GmbH | Pharmaceutical composition comprising a bispecific antibody specific for epcam |
| US20050180979A1 (en) | 2004-02-13 | 2005-08-18 | Micromet Ag | Anti-EpCAM immunoglobulins |
| DE602005024502D1 (de) | 2004-07-09 | 2010-12-16 | Chugai Pharmaceutical Co Ltd | Anti-glypican-3-antikörper |
| CA2585196C (en) | 2004-10-26 | 2015-01-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| PL2142570T3 (pl) | 2007-04-04 | 2011-11-30 | Alfasigma Spa | Przeciwciała skierowane przeciw EPCAM i ich zastosowania |
| PL2178921T3 (pl) | 2007-07-17 | 2016-06-30 | Squibb & Sons Llc | Monoklonalne przeciwciała przeciwko glipikanowi-3 |
| GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| WO2011041093A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US20110165161A1 (en) | 2009-12-23 | 2011-07-07 | Shih-Yao Lin | Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same |
| EP2614077B1 (en) | 2010-09-08 | 2016-08-17 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| EP2699603B1 (en) | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| WO2012153186A2 (en) | 2011-05-06 | 2012-11-15 | Kalgene Pharmaceuticals Inc. | Monoclonal antibodies to epcam-icd and methods for detecting epithelial cancer cells |
| WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| JP6163502B2 (ja) | 2012-03-02 | 2017-07-12 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法 |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US9409994B2 (en) | 2012-06-01 | 2016-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| CN107460201A (zh) | 2013-05-08 | 2017-12-12 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| AU2014331494A1 (en) | 2013-10-02 | 2016-04-07 | Viventia Bio Inc. | Anti-EpCAM antibodies and methods of use |
| ES2939760T3 (es) * | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
| WO2015142661A1 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| US9777061B2 (en) * | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| KR102612313B1 (ko) * | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| EP3174546B1 (en) * | 2014-07-31 | 2019-10-30 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
| PL3183268T3 (pl) * | 2014-08-19 | 2020-09-07 | Novartis Ag | Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego |
| WO2016036973A1 (en) | 2014-09-04 | 2016-03-10 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
| US20170281683A1 (en) | 2014-09-26 | 2017-10-05 | Baylor College Of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
| WO2016115482A1 (en) * | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
-
2017
- 2017-07-24 KR KR1020197004478A patent/KR20190038567A/ko not_active Ceased
- 2017-07-24 US US16/320,055 patent/US20190262397A1/en not_active Abandoned
- 2017-07-24 CA CA3031846A patent/CA3031846A1/en not_active Abandoned
- 2017-07-24 AU AU2017301826A patent/AU2017301826A1/en not_active Abandoned
- 2017-07-24 JP JP2019504106A patent/JP2019530431A/ja not_active Withdrawn
- 2017-07-24 SG SG11201900634VA patent/SG11201900634VA/en unknown
- 2017-07-24 EP EP17749637.9A patent/EP3490589A1/en not_active Withdrawn
- 2017-07-24 WO PCT/EP2017/068654 patent/WO2018019772A1/en not_active Ceased
- 2017-07-24 CN CN201780059507.6A patent/CN110035768A/zh active Pending
- 2017-07-25 TW TW106124862A patent/TW201806969A/zh unknown